Standard Family Office’s Gilead Sciences GILD Stock Holding History

Standard Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-135	Closed	-$12.5K	–	38
2024 Q4	$12.5K	Sell	135 -180	-57%	-$16.2K	0.02%	44
2024 Q3	$26.4K	Hold	315	–	–	0.03%	45
2024 Q2	$21.6K	Hold	315	–	–	0.03%	45
2024 Q1	$23.1K	Buy	+315	New	+$24.2K	0.03%	46
2021 Q3	–	Sell	-5,603	Closed	-$386K	–	259
2021 Q2	$386K	Hold	5,603	–	–	0.08%	100
2021 Q1	$362K	Hold	5,603	–	–	0.09%	86
2020 Q4	$326K	Buy	+5,603	New	+$338K	0.08%	91

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Standard Family Office's GILD Position: Q1 2025 in Review

Standard Family Office sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 135 shares — an estimated $12.5K sold.

Standard Family Office first reported a position in GILD in Q4 2020 and held it in 7 quarters. The position peaked at $386K in Q2 2021. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

Standard Family Office reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
Standard Family Office sold 135 Gilead Sciences shares in Q1 2025, an estimated $12.5K.
Standard Family Office first reported a position in Gilead Sciences in Q4 2020 and held it in 7 quarters.
Standard Family Office's Gilead Sciences position peaked at $386K in Q2 2021.
2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Standard Family Office's 13F filing for Q1 2025, filed 13 May 2025.